Leger S - Search Results

1

L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor.

Gillard J, Ford-Hutchinson AW, Chan C, Charleson S, Denis D, Foster A, Fortin R, Leger S, McFarlane CS, Morton H, et al. Gillard J, et al. Among authors: leger s. Can J Physiol Pharmacol. 1989 May;67(5):456-64. doi: 10.1139/y89-073. Can J Physiol Pharmacol. 1989. PMID: 2548691

2

Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571.

Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Gauthier JY, Leger S, Lord A, Masson P, et al. Jones TR, et al. Among authors: leger s. Can J Physiol Pharmacol. 1991 Dec;69(12):1847-54. doi: 10.1139/y91-273. Can J Physiol Pharmacol. 1991. PMID: 1666333

3

Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D4 receptor antagonist.

Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Frenette R, Gauthier JY, Leger S, Masson P, et al. Jones TR, et al. Among authors: leger s. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. doi: 10.1139/y89-004. Can J Physiol Pharmacol. 1989. PMID: 2540892

4

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al. Chan CC, et al. Among authors: leger s. J Pharmacol Exp Ther. 1999 Aug;290(2):551-60. J Pharmacol Exp Ther. 1999. PMID: 10411562

5

5-Lipoxygenase-activating protein is the target of a novel hybrid of two classes of leukotriene biosynthesis inhibitors.

Mancini JA, Prasit P, Coppolino MG, Charleson P, Leger S, Evans JF, Gillard JW, Vickers PJ. Mancini JA, et al. Among authors: leger s. Mol Pharmacol. 1992 Feb;41(2):267-72. Mol Pharmacol. 1992. PMID: 1538707

6

Characterization of a 5-lipoxygenase-activating protein binding assay: correlation of affinity for 5-lipoxygenase-activating protein with leukotriene synthesis inhibition.

Charleson S, Prasit P, Léger S, Gillard JW, Vickers PJ, Mancini JA, Charleson P, Guay J, Ford-Hutchinson AW, Evans JF. Charleson S, et al. Among authors: leger s. Mol Pharmacol. 1992 May;41(5):873-9. Mol Pharmacol. 1992. PMID: 1588922

7

Structural requirements for the binding of fatty acids to 5-lipoxygenase-activating protein.

Charleson S, Evans JF, Léger S, Perrier H, Prasit P, Wang Z, Vickers PJ. Charleson S, et al. Among authors: leger s. Eur J Pharmacol. 1994 May 17;267(3):275-80. doi: 10.1016/0922-4106(94)90151-1. Eur J Pharmacol. 1994. PMID: 8088366

8

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al. Riendeau D, et al. Among authors: leger s. Br J Pharmacol. 1997 May;121(1):105-17. doi: 10.1038/sj.bjp.0701076. Br J Pharmacol. 1997. PMID: 9146894 Free PMC article.

9

The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor.

Prasit P, Wang Z, Brideau C, Chan CC, Charleson S, Cromlish W, Ethier D, Evans JF, Ford-Hutchinson AW, Gauthier JY, Gordon R, Guay J, Gresser M, Kargman S, Kennedy B, Leblanc Y, Léger S, Mancini J, O'Neill GP, Ouellet M, Percival MD, Perrier H, Riendeau D, Rodger I, Zamboni R, et al. Prasit P, et al. Among authors: leger s. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1773-8. doi: 10.1016/s0960-894x(99)00288-7. Bioorg Med Chem Lett. 1999. PMID: 10406640

10

Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors.

Frenette R, Hutchinson JH, Léger S, Thérien M, Brideau C, Chan CC, Charleson S, Ethier D, Guay J, Jones TR, McAuliffe M, Piechuta H, Riendeau D, Tagari P, Girard Y. Frenette R, et al. Among authors: leger s. Bioorg Med Chem Lett. 1999 Aug 16;9(16):2391-6. doi: 10.1016/s0960-894x(99)00399-6. Bioorg Med Chem Lett. 1999. PMID: 10476875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page